TriangleBiospecimen Collection (NCT03866382)
Biospecimen Collection trial for Bladder Adenocarcinoma (NCT03866382). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with specified rare genitourinary cancers that have spread. Eligibility depends on tumor type, prior therapy and whether disease is confined to bones. No prior cabozantinib is allowed.
The idea: combine daily oral cabozantinib, which blocks growth signals, with intravenous nivolumab and ipilimumab, which aim to support immune attack. Ipilimumab stops after four cycles; cabozantinib and nivolumab continue. Researchers measure tumor response and safety, with treatment lasting up to two years.
This phase 2 study plans 314 patients. NCI sponsors it; 222 US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.